Cargando…
Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion
Secukinumab, an interleukin (IL)-17A antagonist, was associated with disease exacerbations in Crohn’s disease, and de novo cases of inflammatory bowel disease (IBD) have been reported in studies of rheumatoid diseases. However, there has been no detailed report demonstrating the linkage between secu...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American College of Gastroenterology
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072803/ https://www.ncbi.nlm.nih.gov/pubmed/30105273 http://dx.doi.org/10.14309/crj.2018.56 |